Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study.

Breast Cancer Res Treat · 2019 · PMC6533223 · PMID 30796651

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

borderline significantp = 0.06so close (0.05 < p ≤ 0.1)

In low-risk patients, there was a slight ( p = 0.06, borderline significant) decrease in Trait Anxiety: the mean change was − 0.90 points [− 1.86 to + 0.04].

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.